US 12,285,415 B2
Compositions for the treatment of hypertension
Anthony Rodgers, Newtown (AU); and Stephen Macmahon, Newtown (AU)
Assigned to THE GEORGE INSTITUTE FOR GLOBAL HEALTH, Sydney (AU)
Filed by THE GEORGE INSTITUTE FOR GLOBAL HEALTH, Newtown (AU)
Filed on Aug. 8, 2023, as Appl. No. 18/446,268.
Application 18/446,268 is a continuation of application No. 17/932,982, filed on Sep. 16, 2022, granted, now 12,102,623.
Application 17/932,982 is a continuation of application No. 17/014,358, filed on Sep. 8, 2020, granted, now 11,478,462, issued on Oct. 25, 2022.
Application 17/014,358 is a continuation of application No. 16/393,774, filed on Apr. 24, 2019, granted, now 10,799,487, issued on Oct. 13, 2020.
Application 16/393,774 is a continuation of application No. 15/919,923, filed on Mar. 13, 2018, granted, now 10,322,117, issued on Jun. 18, 2019.
Application 15/919,923 is a continuation of application No. PCT/IB2018/000083, filed on Jan. 23, 2018.
Claims priority of provisional application 62/450,324, filed on Jan. 25, 2017.
Prior Publication US 2023/0381161 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4422 (2006.01); A61K 31/277 (2006.01); A61K 31/382 (2006.01); A61K 31/40 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/4418 (2006.01); A61K 31/495 (2006.01); A61K 31/517 (2006.01); A61K 31/549 (2006.01); A61K 31/554 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/4422 (2013.01) [A61K 31/277 (2013.01); A61K 31/382 (2013.01); A61K 31/40 (2013.01); A61K 31/4035 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4418 (2013.01); A61K 31/495 (2013.01); A61K 31/517 (2013.01); A61K 31/549 (2013.01); A61K 31/554 (2013.01); A61P 9/12 (2018.01)] 12 Claims
 
1. A pharmaceutical composition comprising:
(a) telmisartan;
(b) indapamide; and
(c) amlodipine besylate,
wherein the dose of the telmisartan is from about 8 mg to about 12 mg, wherein the dose of indapamide is from about 0.5 mg to about 0.75 mg, wherein the dose of amlodipine besylate is from about 1 mg to about 1.5 mg, and wherein the pharmaceutical composition further comprises a lipid-regulating agent selected from the group consisting of atorvastatin, simvastatin, cerivastatin, fluvastatin, and pravastatin.